Sarah Boyce Adds 19,000 Shares of Contineum Therapeutics

Sarah Boyce, an insider at Contineum Therapeutics, Inc., purchased 19,000 shares of the company on June 26, 2026. This transaction was part of a series of insider buys that same day, reflecting confidence in the company's prospects.

Insider Buying and Selling at Contineum Therapeutics, Inc.

On June 26, 2026, several insiders at Contineum Therapeutics, including Sarah Boyce, Lori Lyons-Williams, Diego Miralles, Todd Brady, Olivia Ware, and Evert Schimmelpennink, each bought 19,000 shares. These transactions, not part of a pre-planned trading program, suggest a unified show of support for the company's future.

Other Institutional Activity in Contineum Therapeutics

In recent activity, Suvretta Capital Management maintained its position in Contineum Therapeutics with 2,841,334 shares worth approximately $37.1 million. Janus Henderson Group increased its stake by 285,857 shares, now holding 2,734,836 shares valued at about $35.6 million, reflecting an 11.7% increase. Meanwhile, Franklin Resources reduced its holdings by 40,140 shares, ending with 1,839,227 shares worth $24.0 million, marking a 2.1% decrease. Balyasny Asset Management cut its position by 157,165 shares, holding 1,685,635 shares valued at $22.0 million, an 8.5% decrease. Millennium Management notably expanded its stake by 704,762 shares, now holding 1,535,449 shares worth about $20.1 million, an 84.8% increase.

Contineum Therapeutics, Inc. Stock Down 16.8%

Shares of NasdaqGS:CTNM traded near $13.36 on Saturday. Contineum Therapeutics has a market cap of approximately $530.5 million and exhibits a beta of 0.89. The stock has seen a 52-week low of $3.72 and a high of $16.33. Its 50-day moving average is $13.02, while the 200-day average stands at $12.53. The company maintains a strong liquidity position with a current ratio of 38.0 and a quick ratio of 37.0.

Analysts Set New Price Targets

Analyst opinions on Contineum Therapeutics remain favorable. On May 14, 2026, Morgan Stanley maintained a hold rating with a $16.00 price target. Earlier, on March 6, 2026, Baird reaffirmed its buy rating with a $20.00 target. The consensus among analysts is a strong buy, with a mean target price of $22.33 based on six opinions.

About Contineum Therapeutics

Contineum Therapeutics, Inc., headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology. Led by CEO Carmine N. Stengone, the company targets conditions such as idiopathic pulmonary fibrosis and chronic pain with its lead asset, PIPE-791. With 51 employees, Contineum continues to innovate in the biotechnology sector.

Bottom Line

Insider buying at Contineum Therapeutics, including Sarah Boyce's acquisition of shares, signals confidence in the company's strategic direction. Investors track such insider activity as a potential indicator of future performance. Remember, these transactions are disclosed after they occur and may not reflect the current position.